It is when the market displays the kind of sentiment it is doing now that most investors develop a strong desire to just get out. That’s qu...

Mutual funds raised their healthcare allocation for the fourth straight month in August 2026 to 8.4%, the highest in 71 months. Experts att...

Valmiki Leela Capital has built a ₹3,000 crore IPO pipeline for the next 12-18 months across renewable energy, power, pharmaceuticals, pack...

India’s semiconductor push is creating a new demand for smarter, more reliable water infrastructure. CN Water’s Shoeb Kurawadwala on locali...

India’s stock market is poised for a broader recovery as four core cycles—macroeconomics, corporate earnings, credit growth, and market sen...

India is entering 2027 with growth opportunities spread across manufacturing, technology, exports, infrastructure, and emerging consumer ma...

Exports under free trade agreements are now growing faster than imports. Outbound shipments to FTA partner countries expanded by 23.9 perce...

The South-South trade has crossed $7 trillion, opening new opportunities for Indian exporters across Africa, ASEAN, the Gulf, and Latin Ame...

The government will fully fund the acquisition of advanced medical testing equipment. Domestic firms are encouraged to seek technology part...

PGIM India Healthcare Fund generated a 22% return over the past year by over-allocating to high-growth segments like CDMO, specialty pharma...

The Indian market was under pressure on Thursday, particularly at the index level. Rising crude-oil prices are an obvious concern, but dome...

Quant Mutual Fund is pivoting away from manufacturing due to rising cost pressures and supply chain issues. Instead, it's channeling invest...

India's economy grew at a brisk 7.8% pace in the recent quarter. Manufacturing, construction, and services sectors drove this strong econom...

Elara has initiated coverage on four pharmaceutical stocks, assigning Buy, Accumulate and Reduce ratings. Alkem Laboratories emerged as its...

Symbiotec Pharmalab's IPO saw strong investor demand, closing oversubscribed 71.26 times. The company aimed to raise Rs 1,757 crore through...

India Inc’s revenue growth is expected to moderate to 13-15% in Q2 FY27 from 21.3% in Q1, ICRA said. Higher input costs could squeeze margi...

The move highlights Huawei's ambitions to gain a foothold in the fast-growing AI drug discovery market, where pharmaceutical companies are ...